Cellular Reprogramming, Inc. provides rapid, low-cost, footprint-free derivation of induced pluripotent stem cells (iPSCs) from human fibroblasts on a fee-for-service basis. Our service uses an advanced form of messenger RNA reprogramming, the fastest, most efficient and most clinically-relevant method of converting fibroblasts to pluripotent stem cells yet devised.
Cellular Reprogramming, Inc. has not listed any services.
Cellular Reprogramming, Inc. performs footprint-free iPSC derivations on human fibroblasts on a fee-for-service basis. Our team has experience making hundreds of patient-specific lines for clients in pharma and academia. The company’s iPSC derivation pipeline is based on an advanced form of mRNA reprogramming that affords the... Show more »
Cellular Reprogramming, Inc. performs footprint-free iPSC derivations on human fibroblasts on a fee-for-service basis. Our team has experience making hundreds of patient-specific lines for clients in pharma and academia. The company’s iPSC derivation pipeline is based on an advanced form of mRNA reprogramming that affords the fastest and most efficient method of converting human fibroblasts into pluripotent stem cells yet devised.
We charge $2000 per line for reprogramming, comprising a non-refundable $500 upfront payment and an on-delivery balance of $1500. Our minimum order is 10 lines ($5K down). Shipping costs are the responsibility of the customer.
Customers should submit a cryovial with ~500K human fibroblasts for each line to be reprogrammed, and must warrant that the submitted cells have tested negative for mycoplasma contamination.
We supply 3 x 1ml replicate cryostocks of iPSCs for each delivered line. We recommend plating the contents of a vial to a single 6-well format well or split between two such wells in 1:2 ratio. Note that we do not offer multiple putative iPSC “clones” isolated by colony picking as we bulk passage nascent colonies from reprogramming plates to establish our passage 1 iPSC cultures. The bulk passaging method is increasingly a preferred practice when using the highly efficient and inherently non-clonal mRNA reprogramming system.
Each iPSC line is delivered with a datasheet presenting phase contrast images and DAPI/OCT4/TRA-1-60 immunostaining demonstrating iPSC morphology and generalized expression of canonical molecular markers. We do not offer functional characterization as a standard service.
Internally, we expand and stabilize iPSCs in the Nutristem/rLN521 culture system. Our customers using other media/substrate combinations report that the cells we provide usually adapt readily on being directly plated in their preferred system. However, recovering to Nutristem/rLN521 first and then transitioning to the in-house culture system is the best approach and should always be considered as a fallback option.
Most of the lines we reprogram spend about a month in culture, from the thawing of the fibroblasts to iPSC freezedown at p3 or later. Overall turnaround time is typically about 45-60 days, allowing for the time required to bring batches of lines into culture and the fact that a minority of lines require extra passages before being release-ready in terms of homogeneity and stability. Turnaround can be affected by other factors including our current workload. Customers with specific time constraints should contact us to discuss timelines before ordering. Work queue priority is determined by the date of purchase order receipt, so long as we have input cells in hand.
Please note that we cannot guarantee a successful iPSC derivation from every line submitted. In general, slow-growing, late-passage lines tend to do less well in reprogramming. Our historical success rate on low-passage (p3-p5) dermal fibroblasts is 90-100%. While we have often attained high success rates even with lower quality material, note that our accelerated, feeder-free reprogramming protocol is not optimized for dealing with aged or refractory fibroblast lines.
We provide iPSCs for research use only (RUO). Any diagnostic or therapeutic use of the iPSCs or their derivatives by the customer or a direct or indirect transferee is strictly prohibited. As a condition of sale, customers agree to be bound by these restrictions and to bind any direct or indirect transferee accordingly. Resale of the iPSCs or their derivatives is prohibited without the written authorization of Cellular Reprogramming, Inc.
Cellular Reprogramming, Inc. has not received any ratings.